    <SEC-DOCUMENT>0001104659-25-040398-index.html : 20250429
    <SEC-HEADER>0001104659-25-040398.hdr.sgml : 20250429
    <ACCEPTANCE-DATETIME>20250428201720
    ACCESSION NUMBER:		0001104659-25-040398
    CONFORMED SUBMISSION TYPE:	S-4/A
    PUBLIC DOCUMENT COUNT:		35
    FILED AS OF DATE:		20250429
    DATE AS OF CHANGE:		20250428

    FILER:

    	COMPANY DATA:
    		COMPANY CONFORMED NAME:			GLYCOMIMETICS INC
    		CENTRAL INDEX KEY:			0001253689
    		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
    		ORGANIZATION NAME:           	03 Life Sciences
    		EIN:				000000000
    		STATE OF INCORPORATION:			DE
    		FISCAL YEAR END:			1231

    	FILING VALUES:
    		FORM TYPE:		S-4/A
    		SEC ACT:		1933 Act
    		SEC FILE NUMBER:	333-285035
    		FILM NUMBER:		25882281

    	BUSINESS ADDRESS:
    		STREET 1:		9708 MEDICAL CENTER DRIVE
    		CITY:			ROCKVILLE
    		STATE:			MD
    		ZIP:			20850
    		BUSINESS PHONE:		240-243-1201

    	MAIL ADDRESS:
    		STREET 1:		9708 MEDICAL CENTER DRIVE
    		CITY:			ROCKVILLE
    		STATE:			MD
    		ZIP:			20850
    </SEC-HEADER>
    <DOCUMENT>
    <TYPE>S-4/A
    <SEQUENCE>1
    <FILENAME>tm256615-9_s4a.htm
    <DESCRIPTION>S-4/A
    <TEXT>
    Document 1 - file: tm256615-9_s4a.htm

    </DOCUMENT>
    <DOCUMENT>
    <TYPE>EX-8.1
    <SEQUENCE>2
    <FILENAME>tm256615d10_ex8-1.htm
    <DESCRIPTION>EXHIBIT 8.1
    <TEXT>
    Document 2 - file: tm256615d10_ex8-1.htm

    </DOCUMENT>
    <DOCUMENT>
    <TYPE>EX-10.30
    <SEQUENCE>3
    <FILENAME>tm256615d10_ex10-30.htm
    <DESCRIPTION>EXHIBIT 10.30
    <TEXT>
    Document 3 - file: tm256615d10_ex10-30.htm

    </DOCUMENT>
    <DOCUMENT>
    <TYPE>EX-10.31
    <SEQUENCE>4
    <FILENAME>tm256615d10_ex10-31.htm
    <DESCRIPTION>EXHIBIT 10.31
    <TEXT>
    Document 4 - file: tm256615d10_ex10-31.htm

    </DOCUMENT>
    <DOCUMENT>
    <TYPE>EX-10.32
    <SEQUENCE>5
    <FILENAME>tm256615d10_ex10-32.htm
    <DESCRIPTION>EXHIBIT 10.32
    <TEXT>
    Document 5 - file: tm256615d10_ex10-32.htm

    </DOCUMENT>
    <DOCUMENT>
    <TYPE>EX-10.33
    <SEQUENCE>6
    <FILENAME>tm256615d10_ex10-33.htm
    <DESCRIPTION>EXHIBIT 10.33
    <TEXT>
    Document 6 - file: tm256615d10_ex10-33.htm

    </DOCUMENT>
    <DOCUMENT>
    <TYPE>EX-10.36
    <SEQUENCE>7
    <FILENAME>tm256615d10_ex10-36.htm
    <DESCRIPTION>EXHIBIT 10.36
    <TEXT>
    Document 7 - file: tm256615d10_ex10-36.htm

    </DOCUMENT>
    <DOCUMENT>
    <TYPE>EX-10.52
    <SEQUENCE>8
    <FILENAME>tm256615d10_ex10-52.htm
    <DESCRIPTION>EXHIBIT 10.52
    <TEXT>
    Document 8 - file: tm256615d10_ex10-52.htm

    </DOCUMENT>
    <DOCUMENT>
    <TYPE>EX-10.53
    <SEQUENCE>9
    <FILENAME>tm256615d10_ex10-53.htm
    <DESCRIPTION>EXHIBIT 10.53
    <TEXT>
    Document 9 - file: tm256615d10_ex10-53.htm

    </DOCUMENT>
    <DOCUMENT>
    <TYPE>EX-10.54
    <SEQUENCE>10
    <FILENAME>tm256615d10_ex10-54.htm
    <DESCRIPTION>EXHIBIT 10.54
    <TEXT>
    Document 10 - file: tm256615d10_ex10-54.htm

    </DOCUMENT>
    <DOCUMENT>
    <TYPE>EX-23.1
    <SEQUENCE>11
    <FILENAME>tm256615d10_ex23-1.htm
    <DESCRIPTION>EXHIBIT 23.1
    <TEXT>
    Document 11 - file: tm256615d10_ex23-1.htm

    </DOCUMENT>
    <DOCUMENT>
    <TYPE>EX-23.2
    <SEQUENCE>12
    <FILENAME>tm256615d10_ex23-2.htm
    <DESCRIPTION>EXHIBIT 23.2
    <TEXT>
    Document 12 - file: tm256615d10_ex23-2.htm

    </DOCUMENT>
    <DOCUMENT>
    <TYPE>EX-23.4
    <SEQUENCE>13
    <FILENAME>tm256615d10_ex23-4.htm
    <DESCRIPTION>EXHIBIT 23.4
    <TEXT>
    Document 13 - file: tm256615d10_ex23-4.htm

    </DOCUMENT>
    <DOCUMENT>
    <TYPE>EX-99.6
    <SEQUENCE>14
    <FILENAME>tm256615d10_ex99-6.htm
    <DESCRIPTION>EXHIBIT 99.6
    <TEXT>
    Document 14 - file: tm256615d10_ex99-6.htm

    </DOCUMENT>
    <DOCUMENT>
    <TYPE>EX-FILING FEES
    <SEQUENCE>15
    <FILENAME>tm256615d10_ex-filingfees.htm
    <DESCRIPTION>EX-FILING FEES
    <TEXT>
    Document 15 - file: tm256615d10_ex-filingfees.htm

    </DOCUMENT>
    <DOCUMENT>
    <TYPE>GRAPHIC
    <SEQUENCE>16
    <FILENAME>bc_inhibitors-4c.jpg
    <DESCRIPTION>GRAPHIC
    <TEXT>
    Document 16 - file: bc_inhibitors-4c.jpg

    </DOCUMENT>
    <DOCUMENT>
    <TYPE>GRAPHIC
    <SEQUENCE>17
    <FILENAME>bc_paidvsnetincome-4c.jpg
    <DESCRIPTION>GRAPHIC
    <TEXT>
    Document 17 - file: bc_paidvsnetincome-4c.jpg

    </DOCUMENT>
    <DOCUMENT>
    <TYPE>GRAPHIC
    <SEQUENCE>18
    <FILENAME>bc_paidvstsr-4c.jpg
    <DESCRIPTION>GRAPHIC
    <TEXT>
    Document 18 - file: bc_paidvstsr-4c.jpg

    </DOCUMENT>
    <DOCUMENT>
    <TYPE>GRAPHIC
    <SEQUENCE>19
    <FILENAME>fc_chemotherapy-4clr.jpg
    <DESCRIPTION>GRAPHIC
    <TEXT>
    Document 19 - file: fc_chemotherapy-4clr.jpg

    </DOCUMENT>
    <DOCUMENT>
    <TYPE>GRAPHIC
    <SEQUENCE>20
    <FILENAME>fc_cr002adc-4c.jpg
    <DESCRIPTION>GRAPHIC
    <TEXT>
    Document 20 - file: fc_cr002adc-4c.jpg

    </DOCUMENT>
    <DOCUMENT>
    <TYPE>GRAPHIC
    <SEQUENCE>21
    <FILENAME>ft_lucidcapnewyork-bw.jpg
    <DESCRIPTION>GRAPHIC
    <TEXT>
    Document 21 - file: ft_lucidcapnewyork-bw.jpg

    </DOCUMENT>
    <DOCUMENT>
    <TYPE>GRAPHIC
    <SEQUENCE>22
    <FILENAME>lc_cooperative-4c.jpg
    <DESCRIPTION>GRAPHIC
    <TEXT>
    Document 22 - file: lc_cooperative-4c.jpg

    </DOCUMENT>
    <DOCUMENT>
    <TYPE>GRAPHIC
    <SEQUENCE>23
    <FILENAME>lc_nsclc-4clr.jpg
    <DESCRIPTION>GRAPHIC
    <TEXT>
    Document 23 - file: lc_nsclc-4clr.jpg

    </DOCUMENT>
    <DOCUMENT>
    <TYPE>GRAPHIC
    <SEQUENCE>24
    <FILENAME>lg_crescent-4clr.jpg
    <DESCRIPTION>GRAPHIC
    <TEXT>
    Document 24 - file: lg_crescent-4clr.jpg

    </DOCUMENT>
    <DOCUMENT>
    <TYPE>GRAPHIC
    <SEQUENCE>25
    <FILENAME>lg_glycomimetics-4c.jpg
    <DESCRIPTION>GRAPHIC
    <TEXT>
    Document 25 - file: lg_glycomimetics-4c.jpg

    </DOCUMENT>
    <DOCUMENT>
    <TYPE>GRAPHIC
    <SEQUENCE>26
    <FILENAME>lg_lucidcapital-bwlr.jpg
    <DESCRIPTION>GRAPHIC
    <TEXT>
    Document 26 - file: lg_lucidcapital-bwlr.jpg

    </DOCUMENT>
    <DOCUMENT>
    <TYPE>GRAPHIC
    <SEQUENCE>27
    <FILENAME>lg_walkers-bwlr.jpg
    <DESCRIPTION>GRAPHIC
    <TEXT>
    Document 27 - file: lg_walkers-bwlr.jpg

    </DOCUMENT>
    <DOCUMENT>
    <TYPE>GRAPHIC
    <SEQUENCE>28
    <FILENAME>ph_antivegf-4c.jpg
    <DESCRIPTION>GRAPHIC
    <TEXT>
    Document 28 - file: ph_antivegf-4c.jpg

    </DOCUMENT>
    <DOCUMENT>
    <TYPE>GRAPHIC
    <SEQUENCE>29
    <FILENAME>ph_cr001-4clr.jpg
    <DESCRIPTION>GRAPHIC
    <TEXT>
    Document 29 - file: ph_cr001-4clr.jpg

    </DOCUMENT>
    <DOCUMENT>
    <TYPE>GRAPHIC
    <SEQUENCE>30
    <FILENAME>ph_vegf-4clr.jpg
    <DESCRIPTION>GRAPHIC
    <TEXT>
    Document 30 - file: ph_vegf-4clr.jpg

    </DOCUMENT>
    <DOCUMENT>
    <TYPE>GRAPHIC
    <SEQUENCE>31
    <FILENAME>sg_lucidcapitalmarkets-bw.jpg
    <DESCRIPTION>GRAPHIC
    <TEXT>
    Document 31 - file: sg_lucidcapitalmarkets-bw.jpg

    </DOCUMENT>
    <DOCUMENT>
    <TYPE>GRAPHIC
    <SEQUENCE>32
    <FILENAME>tb_clinicaldevelop-4c.jpg
    <DESCRIPTION>GRAPHIC
    <TEXT>
    Document 32 - file: tb_clinicaldevelop-4c.jpg

    </DOCUMENT>
    <DOCUMENT>
    <TYPE>GRAPHIC
    <SEQUENCE>33
    <FILENAME>tb_pfs-4c.jpg
    <DESCRIPTION>GRAPHIC
    <TEXT>
    Document 33 - file: tb_pfs-4c.jpg

    </DOCUMENT>
    <DOCUMENT>
    <TYPE>GRAPHIC
    <SEQUENCE>34
    <FILENAME>tm256615d10_ex8-1img01.jpg
    <DESCRIPTION>GRAPHIC
    <TEXT>
    Document 34 - file: tm256615d10_ex8-1img01.jpg

    </DOCUMENT>
    <DOCUMENT>
    <TYPE>GRAPHIC
    <SEQUENCE>35
    <FILENAME>tm256615d10_ex23-4img001.jpg
    <DESCRIPTION>GRAPHIC
    <TEXT>
    Document 35 - file: tm256615d10_ex23-4img001.jpg

    </DOCUMENT>
    </SEC-DOCUMENT>